A phase 1 trial of the anti-inhibitory KIR mAb IPH2101 for AML in complete remission

Norbert Vey(Centre de Recherche en Cancérologie de Marseille), Daniel Olive(Centre National de la Recherche Scientifique), Aude Charbonnier(Institut Paoli-Calmettes), Thomas Prébet(Yale University), Nicolas Boissel(Inserm), Jean Bourhis(University of Lausanne), Dominique Bordessoule(Centre Hospitalier Universitaire de Limoges), Don Benson(The Ohio State University), Pascale André(Innate Pharma (France)), Hervé Dombret(University of London Institute in Paris), Anne Etienne(Aix-Marseille Université), François Romagné(Innate Pharma (France))
Blood
September 23, 2012
10.1182/blood-2012-06-437558
Cited by 269

Related Papers

Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
|Blood|2009|3.4k
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3.1k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Defining risk levels in locally advanced head and neck cancers: A comparative analysis of concurrent postoperative radiation plus chemotherapy trials of the EORTC (#22931) and RTOG (# 9501)
|Head & Neck|2005|1.8k